U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H27O2.H4N
Molecular Weight 245.4014
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMMONIUM MYRISTATE

SMILES

[NH4+].CCCCCCCCCCCCCC([O-])=O

InChI

InChIKey=BJOYVZZDDFVLPI-UHFFFAOYSA-N
InChI=1S/C14H28O2.H3N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;/h2-13H2,1H3,(H,15,16);1H3

HIDE SMILES / InChI

Description

Ammonium myristate is passage-delaying substance. It was used as a substance for influencing gastrointestinal passage. The addition of ammonium myristate caused a delay of about 1.5 h in the transit time of the absorbing part of the gastrointestinal tract. The addition of ammonium myristate improves the availability of nitrofurantoin from a slow releasing dosage form - an average increase is 23.8% of the total amount of nitrofurantoin excreted in the urine compared to the values obtained from the reference dosage form without the additional substance. The kinetics of renal elimination of nitrofurantoin is characterized by the longer duration of urinary excretion.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown
Diagnostic
Unknown
Inactive ingredient
Volu-Firm

PubMed

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Rous sarcoma virus-transformed cells were labeled for 2 h with either 1 mCi of [3H]palmitic acid or 0.2 mCi of [3H]myristic acid, and p60src was isolated by immunoprecipitation. The incorporation of [3H]myristic acid into p60src was ca. 100-fold greater than the incorporation of [3H]palmitic acid.